Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
NAD+ is a ubiquitous redox cofactor and enzyme substrate—not a peptide. Research distinguishes direct NAD+ exposure from precursor compounds such as NR and NMN.
Key points
- The compound is nicotinamide adenine dinucleotide, a dinucleotide central to redox reactions and signalling enzymes.
- Evidence from cells, animals and humans must be interpreted separately.
- NAD+ research material is not thereby authorised as a medicine; product classification depends on presentation, intended purpose and jurisdiction.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
NAD+ is a ubiquitous redox cofactor and enzyme substrate—not a peptide. Research distinguishes direct NAD+ exposure from precursor compounds such as NR and NMN. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
NAD+/NADH couples support cellular redox chemistry, while NAD+ is consumed by enzymes including sirtuins, PARPs and CD38. Direct extracellular NAD+, NR, NMN and niacin follow different metabolic pathways and should not be treated as interchangeable.
What does the current evidence show?
- A small pilot mapped plasma and urinary metabolites during a six-hour direct NAD+ infusion but did not establish efficacy.
- A 2026 retrospective commercial-clinic study reported tolerability differences between NAD+ and NR infusions, with important design limitations.
- Randomised human evidence is larger for oral precursors than for direct NAD+, and physiological benefits remain inconsistent.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Raising a blood metabolite does not necessarily improve a clinical outcome.
- Evidence for NR or NMN cannot be assigned to direct NAD+.
- Direct-infusion research is small, heterogeneous and often uncontrolled.
Regulatory and safety context
NAD+ research material is not thereby authorised as a medicine; product classification depends on presentation, intended purpose and jurisdiction. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
- Direct NAD+ infusion pilot — PubMed
- 2026 retrospective pilot — PubMed
- Critical review of human NR studies — PubMed
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.